Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer
Read More
Resource Library
-
-
Circulating tumor DNA (ctDNA) dynamics in patients receiving capecitabine (CAPE) for early-stage triple-negative breast cancer
Read More
-
Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with breast cancer (BC)
Read More
-
Monitoring response to neoadjuvant chemotherapy in Triple Negative Breast Cancer using circulating tumor DNA
Read More
-
Have a question or comment?
Contact Us -
Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery
Read More
-
NIPT for 22q11.2 DS: Does evidence support routine screening?
During this webinar series, Natera’s medical leadership team will review publications with significant findings from SNP-based NIPT results.
Watch Video
-
Breast Cancer Patient Discussion Guide
Read More
-
Breast Cancer Patient Brochure
Read More
-
Natera's Environmental Policy
Read More
-
Nominating, Corporate Governance and Compliance Committee Charter
Read More
-
Code of Conduct
Read More
-
Performance of Donor-Derived Cell-Free DNA in Repeat Kidney Transplant Recipients
Read More
-
Elevations from Baseline dd-cfDNA Fraction are Associated with Acute Allograft Rejection in Kidney Transplant Recipients
Read More
-
Donor-Derived cfDNA Fraction Levels in Stable Kidney Transplant Recipients in the First Year After Transplant
Read More
-
Signatera CRC Brochure
Read More
-
Signatera IO One Sheet
Read More
-
Circulate Japan Sales Aid
Read More
-
Oncology Pan Portfolio
Read More
-
ISHLT 2023 Lung Symposium
Watch Video
-
Prospera Kidney - Increased Risk Result Video
Please watch this short video explaining what your results may mean for you.
Watch Video
-
Loading More...
